Mayne Pharma Valuation
| MAYNF Stock | USD 2.62 0.01 0.38% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Mayne Pharma Group secures a last-minute Real Value of $2.36 per share. The latest price of the firm is $2.62. Our model forecasts the value of Mayne Pharma Group from analyzing the firm fundamentals such as Profit Margin of (0.62) %, current valuation of 448.85 M, and Return On Equity of -0.41 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Mayne Pharma's price fluctuation is unstable at this time. Calculation of the real value of Mayne Pharma Group is based on 3 months time horizon. Increasing Mayne Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mayne pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Mayne Pharma Group. Since Mayne Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mayne Pink Sheet. However, Mayne Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.62 | Real 2.36 | Hype 2.62 |
The real value of Mayne Pink Sheet, also known as its intrinsic value, is the underlying worth of Mayne Pharma Group Company, which is reflected in its stock price. It is based on Mayne Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Mayne Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Mayne Pharma Group helps investors to forecast how Mayne pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mayne Pharma more accurately as focusing exclusively on Mayne Pharma's fundamentals will not take into account other important factors: Mayne Pharma Total Value Analysis
Mayne Pharma Group is now estimated to have takeover price of 448.85 M with market capitalization of 235.41 M, debt of 413.67 M, and cash on hands of 98.01 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mayne Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
448.85 M | 235.41 M | 413.67 M | 98.01 M |
Mayne Pharma Investor Information
About 23.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mayne Pharma Group recorded a loss per share of 0.03. The entity last dividend was issued on the 18th of January 2023. The firm had 987:937 split on the 30th of June 2016. Based on the key measurements obtained from Mayne Pharma's financial statements, Mayne Pharma Group is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Mayne Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mayne Pharma has an asset utilization ratio of 32.91 percent. This implies that the Company is making $0.33 for each dollar of assets. An increasing asset utilization means that Mayne Pharma Group is more efficient with each dollar of assets it utilizes for everyday operations.Mayne Pharma Ownership Allocation
Mayne Pharma Group maintains a total of 1.74 Billion outstanding shares. Mayne Pharma Group holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Mayne Pharma Profitability Analysis
The company reported the revenue of 423.92 M. Net Loss for the year was (263.34 M) with profit before overhead, payroll, taxes, and interest of 171.03 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Mayne Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Mayne Pharma and how it compares across the competition.
About Mayne Pharma Valuation
The pink sheet valuation mechanism determines Mayne Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Mayne Pharma. We calculate exposure to Mayne Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mayne Pharma's related companies.Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Mayne Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Mayne Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Mayne Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Mayne Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Mayne Pharma's revenue streams: Identify Mayne Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Mayne Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Mayne Pharma's growth potential: Evaluate Mayne Pharma's management, business model, and growth potential.
- Determine Mayne Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Mayne Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Mayne Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Mayne Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.8 B | |
| Forward Price Earnings | 277.7778 | |
| Retained Earnings | -822.4 M |
Complementary Tools for Mayne Pink Sheet analysis
When running Mayne Pharma's price analysis, check to measure Mayne Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mayne Pharma is operating at the current time. Most of Mayne Pharma's value examination focuses on studying past and present price action to predict the probability of Mayne Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mayne Pharma's price. Additionally, you may evaluate how the addition of Mayne Pharma to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |